AI Engines For more Details: Perplexity Kagi Labs You
Digestive Health: Bifidobacterium adolescentis may contribute to digestive health by promoting the balance of gut microbiota. It can help improve digestion, alleviate symptoms of gastrointestinal disorders such as irritable bowel syndrome (IBS), and reduce the risk of diarrhea and constipation.
Immune Support: This probiotic strain may modulate the immune system, helping to enhance immune function and reduce the risk of infections, particularly in the gut. It may also contribute to reducing inflammation in the gastrointestinal tract.
Metabolic Health: Bifidobacterium adolescentis has been studied for its potential role in metabolic health. It may help improve blood sugar control, lipid metabolism, and weight management. By reducing insulin resistance and promoting a healthy body weight, it may contribute to lowering the risk of metabolic disorders such as diabetes and obesity.
Vaginal Health: Some research suggests that certain strains of Bifidobacterium, including Bifidobacterium adolescentis, may play a role in maintaining a healthy vaginal microbiota. By preventing the overgrowth of harmful bacteria and fungi, it may reduce the risk of vaginal infections and contribute to overall vaginal health.
Inflammatory Conditions: Bifidobacterium adolescentis may have anti-inflammatory properties that could be beneficial in conditions characterized by inflammation, such as inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. By modulating the immune response and reducing inflammation in the gut, it may help alleviate symptoms and improve disease management.
Mental Health: There is emerging evidence suggesting that the gut microbiota, including certain Bifidobacterium strains, may influence mental health and cognitive function. Bifidobacterium adolescentis may help support mood and reduce symptoms of anxiety and depression by interacting with the gut-brain axis and influencing neurotransmitter production.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.6 | -2 |
Acne | 3.1 | 0.8 | 2.88 |
ADHD | 5.1 | 1.7 | 2 |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.6 | 0 |
Allergic Rhinitis (Hay Fever) | 0.4 | 2.3 | -4.75 |
Allergies | 2.2 | 3.3 | -0.5 |
Allergy to milk products | 0.3 | 3.6 | -11 |
Alopecia (Hair Loss) | 0.7 | 1.7 | -1.43 |
Alzheimer's disease | 5.4 | 4.2 | 0.29 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.5 | 3.6 | -1.4 |
Ankylosing spondylitis | 2.1 | 3.4 | -0.62 |
Anorexia Nervosa | 2.7 | 1 | 1.7 |
Asthma | 2.2 | 0.9 | 1.44 |
Atherosclerosis | 2 | 2 | 0 |
Atrial fibrillation | 1.4 | 1.8 | -0.29 |
Autism | 7.8 | 6.7 | 0.16 |
Barrett esophagus cancer | 0.8 | 0.6 | 0.33 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 3.4 | 3.3 | 0.03 |
Brain Trauma | 2.3 | 0.4 | 4.75 |
Breast Cancer | 0.5 | 0.5 | |
Carcinoma | 2.2 | 2.6 | -0.18 |
Celiac Disease | 5.3 | 0.8 | 5.62 |
Cerebral Palsy | 1.6 | 0.6 | 1.67 |
Chronic Fatigue Syndrome | 4 | 2.1 | 0.9 |
Chronic Kidney Disease | 2.7 | 0.8 | 2.38 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.1 | -0.22 |
Chronic Urticaria (Hives) | 2.2 | 2.2 | |
Coagulation / Micro clot triggering bacteria | 0.7 | 0.6 | 0.17 |
Colorectal Cancer | 1.8 | 3.3 | -0.83 |
Constipation | 2.4 | 1 | 1.4 |
Coronary artery disease | 1.3 | 1.8 | -0.38 |
COVID-19 | 8.2 | 5.2 | 0.58 |
Crohn's Disease | 7.7 | 5.3 | 0.45 |
cystic fibrosis | 0.9 | 0.6 | 0.5 |
deep vein thrombosis | 0.7 | 0.7 | |
Depression | 9.1 | 5.6 | 0.63 |
Dermatomyositis | 0.8 | 0.3 | 1.67 |
Eczema | 1.9 | -1.9 | |
Endometriosis | 1.2 | 4.2 | -2.5 |
Eosinophilic Esophagitis | 1.6 | 0.3 | 4.33 |
Epilepsy | 3 | 3.3 | -0.1 |
erectile dysfunction | 0.3 | 0.5 | -0.67 |
Fibromyalgia | 1.3 | 1.6 | -0.23 |
Functional constipation / chronic idiopathic constipation | 3.4 | 4.6 | -0.35 |
gallstone disease (gsd) | 1.2 | 1.3 | -0.08 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.9 | 0.22 |
Generalized anxiety disorder | 1.7 | 1.7 | |
giant cell arteritis | 0.6 | -0.6 | |
Glioblastoma | 1.8 | 1.8 | |
Gout | 1.5 | 1.6 | -0.07 |
Graves' disease | 2.5 | 3.4 | -0.36 |
Halitosis | 0.8 | -0.8 | |
Hashimoto's thyroiditis | 1.2 | 1.1 | 0.09 |
Hemorrhoidal disease, Hemorrhoids, Piles | 0.1 | 0.1 | |
Hidradenitis Suppurativa | 0.3 | 0.6 | -1 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.3 | 1.3 | |
hypercholesterolemia (High Cholesterol) | 1.4 | 2 | -0.43 |
hyperglycemia | 0.8 | 1.7 | -1.13 |
Hyperlipidemia (High Blood Fats) | 1.4 | 0.4 | 2.5 |
hypersomnia | 0.7 | 0.2 | 2.5 |
hypertension (High Blood Pressure | 3.9 | 3.4 | 0.15 |
Hypothyroidism | 2 | 0.7 | 1.86 |
Hypoxia | 0.6 | 0.6 | |
IgA nephropathy (IgAN) | 0.8 | 1 | -0.25 |
Inflammatory Bowel Disease | 3.7 | 2.1 | 0.76 |
Insomnia | 2 | 0.9 | 1.22 |
Intelligence | 2.2 | 1.7 | 0.29 |
Intracranial aneurysms | 0.8 | 1.6 | -1 |
Irritable Bowel Syndrome | 4.6 | 3.8 | 0.21 |
Juvenile idiopathic arthritis | 0.3 | 0.3 | |
Liver Cirrhosis | 3.6 | 3.4 | 0.06 |
Long COVID | 11 | 6.2 | 0.77 |
Low bone mineral density | 1.6 | 1.6 | |
Lung Cancer | 3 | 0.2 | 14 |
ME/CFS with IBS | 1.6 | 1.6 | |
ME/CFS without IBS | 1 | 0.4 | 1.5 |
Menopause | 0.2 | 0.2 | |
Metabolic Syndrome | 8.4 | 7.5 | 0.12 |
Mood Disorders | 9.1 | 9 | 0.01 |
multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
Multiple Sclerosis | 4.3 | 3 | 0.43 |
Multiple system atrophy (MSA) | 0.4 | 0.4 | |
Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
neuropsychiatric disorders (PANDAS, PANS) | 2.6 | 0.4 | 5.5 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.8 | 4 | 0.2 |
Obesity | 8.2 | 7.3 | 0.12 |
obsessive-compulsive disorder | 3.9 | 1.6 | 1.44 |
Osteoarthritis | 1.8 | 0.3 | 5 |
Osteoporosis | 2 | 1.6 | 0.25 |
pancreatic cancer | 0.7 | 0.3 | 1.33 |
Parkinson's Disease | 4.8 | 2.7 | 0.78 |
Polycystic ovary syndrome | 1.7 | 3.2 | -0.88 |
Postural orthostatic tachycardia syndrome | 0.6 | 0.6 | |
Premenstrual dysphoric disorder | 0.3 | 0.2 | 0.5 |
primary biliary cholangitis | 0.5 | 1.4 | -1.8 |
Psoriasis | 1.5 | 2.1 | -0.4 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.6 | 6.1 | -0.09 |
Rosacea | 0.3 | 1.2 | -3 |
Schizophrenia | 3.8 | 5.7 | -0.5 |
scoliosis | 1 | 1.2 | -0.2 |
sensorineural hearing loss | 0.3 | 0.3 | 0 |
Sjögren syndrome | 3.6 | 2.2 | 0.64 |
Sleep Apnea | 1.6 | 1.9 | -0.19 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.9 | -2 |
Stress / posttraumatic stress disorder | 3.2 | 1.6 | 1 |
Systemic Lupus Erythematosus | 5.8 | 3.1 | 0.87 |
Tic Disorder | 2.1 | 1.9 | 0.11 |
Tourette syndrome | 0.3 | 0.3 | |
Type 1 Diabetes | 2.3 | 3.3 | -0.43 |
Type 2 Diabetes | 6.4 | 6.4 | 0 |
Ulcerative colitis | 6.3 | 4.1 | 0.54 |
Unhealthy Ageing | 2.4 | 1.2 | 1 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.